Diversity Best Practices
New York, NY, August 18, 2020—Diversity Best Practices (DBP), a division of Working Mother Media, unveiled its fourth annual Inclusion Index. The index helps organizations understand trends and gaps in demographic representation, creates a road map to drive internal change, and identifies diversity, equity and inclusion (DE&I) solutions to close the gaps. Organizations provided data and were measured in three key areas: best practices in the recruitment, retention and advancement of people from underrepresented groups—women, racial/ethnic minorities, people with disabilities, and LGBTQ people; inclusive corporate culture, including leadership accountability; and demographic diversity for women and racial/ethnic minorities.
Roche Diagnostics was among the 98 organizations that earned a score of at least 60 percent and a place on the index. This year, 185 organizations participated in the Diversity Best Practices Inclusion Index, a 25 percent year-over-year increase. Twenty of those listed on the 2020 DBP Inclusion Index are recognized for superior achievement by receiving an 81 percent or higher score and qualifying as a Top 10 Percent Inclusion Index Company. Nine of those listed achieved at least 75 percent of the available points to qualify as a Leading Inclusion Index Company. Completed applications were collected online from December 2019 through March 2020. Results reveal opportunities for all organizations to target their diversity and inclusion efforts for greater effectiveness.
“Diversity, equity and inclusion continues to be a topic of critical importance, especially in these times of heightened racism and social injustice,” says Deborah Munster, vice president, Diversity Best Practices. “The good news is that corporate America is paying closer attention to its D&I practices, and I am proud to recognize the work our Inclusion Index companies are doing to elevate their efforts to drive a more equitable future.”
“The recent racial injustices we’ve seen in the U.S. shine an even bigger spotlight on the diversity & inclusion efforts at Roche and elsewhere,” says Chris Krull, Roche Diagnostics diversity and inclusion director. “We know that our colleagues and candidates want to work for a company where they can feel included, respected and supported while being 100% their authentic selves. That’s why we’re thrilled to appear on the Diversity Best Practice Index for the second year in a row.”
Key findings from the 2020 Diversity Best Practices Inclusion Index are:
Recruitment, retention and advancement: While 100 percent of the top 10 percent require diverse interview slates, requiring diverse panels of interviewers remains less common at 75 percent of Leading Inclusion Index companies (compared to 45 percent of companies on the index). One hundred percent of the top 10 percent and of Leading Inclusion Index organizations, and 97 percent of those on the index, use employee resource groups to recruit underrepresented talent. Eighty-five percent of the top 10 percent organizations require gender and racial/ethnic diversity in succession planning (compared with 79 percent of Leading Inclusion Index organizations and 59 percent of companies on the index).
Inclusive corporate culture: Ninety-five percent of the top 10 percent organizations set percentages goals in diversity (compared with 90 percent of Leading Inclusion Index companies and 65 percent of index companies). Sixty-five percent of the top 10 percent organizations compensate managers for DE&I results (compared with 62 percent of Leading Inclusion Index companies and 42 percent of index companies).
Diversity Best Practices, a division of Working Mother Media, is the preeminent organization for diversity thought leaders to share best practices and develop innovative solutions for culture change. Through research, benchmarking, publications and events, DBP offers members information and strategies on how to implement, grow, measure and create first-in-class diversity programs.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognized as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.